SCHEMBL6632780

SCHEMBL6632780

OC1[CH]Cc2ccc(F)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.39
HTR2A P28223 1/20 0.39
KDM1A O60341 4/20 0.36
KDM1B Q8NB78 1/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
ACHE P22303 1/20 0.33
OPRM1 P35372 1/20 0.33
DPP8 Q6V1X1 2/20 0.31
CA3 P07451 1/20 0.31
CA6 P23280 1/20 0.31
CA5A P35218 1/20 0.31
CA9 Q16790 1/20 0.31
CA14 Q9ULX7 1/20 0.31
CA5B Q9Y2D0 1/20 0.31
DPP9 Q86TI2 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27832946 0.84 CHRNB2 (0.37) HTR2CHTR2AKDM1AKDM1BCHRNB2
SCHEMBL6763552 0.70 HTR2A (0.38) HTR2CHTR2A
SCHEMBL3078945 0.70 HTR2A (0.38) HTR2CHTR2A
SCHEMBL528662 0.70 HTR2A (0.38) HTR2CHTR2A
SCHEMBL1154662 0.68 HTR2C (0.46) HTR2CHTR2AKDM1AKDM1B
SCHEMBL16698284 0.68 HTR2C (0.46) HTR2CHTR2AKDM1AKDM1B
SCHEMBL27563375 0.66 CHRNB2 (0.39) HTR2CKDM1AKDM1BCHRNB2CHRNB4
SCHEMBL6632249 0.65 KDM1A (0.46) HTR2CHTR2AKDM1AKDM1BACHE
SCHEMBL11822622 0.65 PIN1 (0.46) HTR2CHTR2AOPRM1
SCHEMBL22143619 0.65 HTR2A (0.44) HTR2CHTR2AKDM1AOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317459-B1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS ASTRAZENECA AB (SE) 2004-04-07 EP disclosed
US-20030232875-A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors ASTRAZENECA AB (SE) 2003-12-18 US disclosed
EP-1317459-A1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS AstraZeneca AB (SE) 2003-06-11 EP disclosed
WO-2002020530-A1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS ASTRAZENECA AB (SE) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232875-A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors GYS1, GYS2, PYGL HTR2C 2494/4885HTR2A 3403/4885KDM1A 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.